Skip to main content

Table 3 Concordance between changes in serum thymidine kinase and changes in Ki-67 by palbociclib

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

 

Ki-67 ↓ (N)

Ki-67 ↑ (N)

Total (N)

TK ↓ (n)

32

4a

36

TK ↑ (n)

2a

21

23

Total (n)

34

25

59

  1. TK, Thymidine kinase
  2. a Discordant cases
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us